Allogene is focused on setting a higher bar for CLL treatment with our innovative ALPHA2 trial. By using healthy donor cells for CAR T products, we aim to overcome limitations of autologous CAR T and provide a clinically meaningful advance for late-stage patients. #ALLO #CART #celltherapy #immunotherapy Learn How We Are Raising the Bar in CLL: Allogene.com/Pipeline
Allogene Therapeutics
Biotechnology
South San Francisco, California 63,108 followers
About us
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
-
www.allogene.com
External link for Allogene Therapeutics
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Locations
-
Primary
Get directions
210 E Grand Ave
South San Francisco, California 94080, US
-
Get directions
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Updates
-
Fantastic day of discussion at the US Pharma and Biotech Summit! Our very own David Chang, MD, PhD, President and CEO, participated in an enlightening session exploring avenues to deliver cell and gene therapies to more patients. #biopharma #celltherapy #CART #allogeneic
A formidable panel to discuss delivering #CGTs to the masses at today's Financial Times US Pharma and Biotech Summit in #NYC. Speakers from Kyowa Kirin Co., Ltd., Astellas Pharma, Kite Pharma, Allogene Therapeutics, and Bayer holding an interactive discussion. #pharma #biotechnology #celltherapies #genetherapies
-
-
Thrilled to see our own Zachary J Roberts MD PhD featured in this report to discuss the potential of investigational allogeneic CAR T products.
HOT OF THE PRESS: The New Era of Life Sciences 2024 This report captures a historical moment for life sciences. What were dreams or vague projections until recently are now solidifying realities. Highly personalized oncology therapies, the possibility of early cancer detection via a simple blood draw, AI’s optimization of drug discovery, unseen breakthroughs in the formerly stagnating fields of neurology or dermatology - inspiring illustrations of each of these, and more, can be found in this piece, the result of more than 100 conversations with industry leaders. Dive deep into 'The New Era of Life Sciences' report, a comprehensive exploration of the advancements shaping healthcare and beyond. READ FULL REPORT: https://lnkd.in/diZsNp3i
-
-
Looking forward to having Allogene's Zachary J Roberts MD PhD join Arie Belldegrun, MD for the Meet the Experts in Drug Development panel at #LABEST2024 on May 23! Check Out the Event Agenda: https://lnkd.in/dt4jw7bC
-
-
Find today's RBC Capital Markets Global Healthcare Conference fireside chat with David Chang, MD, PhD, President and CEO of Allogene, moderated by Luca Issi in the investors section of our website. #CART #celltherapy #immunotherapy Join us for an Allogene Fireside Chat: https://lnkd.in/grwuiKC7
-
-
Pleased to report our Q1 2024 corporate update and business highlights. Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update: https://lnkd.in/giFYSeik
-
David Chang, MD, PhD, President and CEO of Allogene will join a panel discussion on May 16 at the US Pharma and Biotech Summit hosted by Financial Times and Endpoints News. $ALLO #FTPharma #CART #celltherapy #immunotherapy Learn More: https://lnkd.in/gpxN_-z5
-
-
Investigational AlloCAR T™ products are designed to overcome limitations of autologous therapies and deliver these transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access: Allogene.com/Pipeline
-
Join us for our Q1 2024 conference call on Monday, May 13 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. https://lnkd.in/g9CyXunH